Canadians Now Have More Options to Treat Hodgkin Lymphoma
Seattle Genetics, Inc. has announced that Health Canada has approved ADCETRIS as post-autologous stem cell transplant (ASCT) postremission therapy for patients affected by Hodgkin lymphoma (HL) who are a higher risk of advancement or relapse. Positive results from phase three AETHREA clinical trials helped to approve the medication. ADCETRIS has been approved in Canada already for HL patients who relapsed after their ASCT or who relapsed after two multi-agent chemotherapy procedures who weren’t able to have an ASCT and for systemic anaplastic large cell lymphoma (sALCL) patients who have relapsed after a multi-agent chemotherapy procedure.
Clay Siegall, President and Chief Executive Officer of Seattle Genetics, says with the expanding of the ADCETRIS label, Canadian doctors and patients will have more access to treat their HL. He says this is a great milestone toward expanding ADCETRIS availability globally to patients who need this important medication. Dr. Siegall also said a license application has been submitted to the Food and Drug Administration (FDA) for ADCETRIS approval in cutaneous T-cell lymphoma, which would also be submitted to Health Canada for approval.